AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22302652 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the US for more than a quarter of their lifetime
Number of subjects: 877
Study 22302652 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a regular physician
Number of subjects: 877
Study 22302652 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's recommendation
Number of subjects: 877
Study 22302652 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 877
Study 20863389 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/m² Cisplatin (group I; 16 patients)
Number of subjects: 31
Study 20863389 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/m² Paclitaxel (group II; 15 patients)
Number of subjects: 31
Study 18395723 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (135 mg daily for 6 months)
Number of subjects: 96
Study 18395723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 16320434 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a sexual partner
Number of subjects: 245
Study 16320434 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with family or friends
Number of subjects: 245
Study 16320434 — intervention group
Group type: COMPARATOR
Intervention: Being responsible for children or others
Number of subjects: 245
Study 14551299 — intervention group
Group type: COMPARATOR
Intervention: Standard timed (ST) doxorubicin 60 mg/m2 plus cisplatin 60 mg/m2
Number of subjects: 342
Study 14551299 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian timed (CT) doxorubicin 60 mg/m2 at 6:00 am plus cisplatin 60 mg/m2 at 6:00 pm
Number of subjects: 342
Study 10827336 — intervention group
Group type: EXPERIMENTAL
Intervention: Baggy condom
Number of subjects: 104
Study 10827336 — intervention group
Group type: COMPARATOR
Intervention: Standard condom
Number of subjects: 104
Study 8880110 — intervention group
Group type: EXPERIMENTAL
Intervention: Manoeuvre No. 1 (rapid inspiration with a 2 s end‐inspiratory breathhold)
Number of subjects: 25
Study 8880110 — intervention group
Group type: EXPERIMENTAL
Intervention: Manoeuvre No. 2 (rapid inspiration without an end‐inspiratory breathhold)
Number of subjects: 25
Study 8880110 — intervention group
Group type: EXPERIMENTAL
Intervention: Manoeuvre No. 3 (slow inspiration lasting about 5 s with an end‐inspiratory breathhold of at least 4 s)
Number of subjects: 25
Study 1539514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic, low‐osmolar iohexol
Number of subjects: 22
Study 1539514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic, low‐osmolar ioxaglate meglumine
Number of subjects: 22
Study 1539514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic, high‐osmolar meglumine diatrizoate
Number of subjects: 22
Study 1539514 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary papaverine (10 mg)
Number of subjects: 22
Study 1539514 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary nitroglycerin (200 micrograms)
Number of subjects: 22
Study 1539514 — intervention group
Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 22
Study 4033706 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (268 g per day)
Number of subjects: 6
Study 4033706 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (19 g per day)
Number of subjects: 6
Study 31908102 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind map-based life review programme (MBLRP)
Number of subjects: 84
Study 31908102 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 84
Study 30567532 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 176
Study 27565437 — intervention group
Group type: EXPERIMENTAL
Intervention: adolescent text only
Number of subjects: 25
Study 27565437 — intervention group
Group type: EXPERIMENTAL
Intervention: adolescent and caregiver text plus communication
Number of subjects: 25
Study 27565437 — intervention group
Group type: EXPERIMENTAL
Intervention: adolescent application only
Number of subjects: 25
Study 27565437 — intervention group
Group type: EXPERIMENTAL
Intervention: adolescent and caregiver application plus communication
Number of subjects: 25
Study 27565437 — intervention group
Group type: EXPERIMENTAL
Intervention: epilepsy application for adolescents only
Number of subjects: 25
Study 26448506 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 102
Study 26448506 — intervention group
Group type: EXPERIMENTAL
Intervention: MECC
Number of subjects: 102
Study 26448506 — intervention group
Group type: COMPARATOR
Intervention: ONCAB
Number of subjects: 102
Study 23897038 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg/kg of body weight twice daily)
Number of subjects: 283
Study 23897038 — intervention group
Group type: EXPERIMENTAL
Intervention: combined genotypes (HTR3A/HTR3B and SLC6A4‐LL/TT)
Number of subjects: 283
Study 21560011 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached pushing during the second stage of labor
Number of subjects: 128
Study 21560011 — intervention group
Group type: COMPARATOR
Intervention: Non-coached pushing during the second stage of labor
Number of subjects: 128
Study 18201285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated plasma separation and adsorption (FPSA)
Number of subjects: 4
Study 18201285 — intervention group
Group type: COMPARATOR
Intervention: High flux hemodialysis (HD)
Number of subjects: 4
Study 16601642 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual treatment plus family psychoeducation
Number of subjects: 41
Study 16601642 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 41
Study 12749524 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based home telecare
Number of subjects: 0
Study 12749524 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls
Number of subjects: 0
Study 12749524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12749524 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person visits
Number of subjects: 0
Study 12749524 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 11191690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine with behavior therapy (20 sessions)
Number of subjects: 10
Study 11191690 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine alone
Number of subjects: 10
Study 8623947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 186
Study 8623947 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 186
Study 8623947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 186
Study 1449045 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (hGH) 0.1 IU.kg‐1 body weight.d‐1
Number of subjects: 16
Study 1449045 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 16
Study 1449045 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (hGH)
Number of subjects: 16
Study 3904700 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative healing agents
Number of subjects: 18
Study 3904700 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 18
Study 30315763 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 50
Study 29474289 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Q‐tip touch test, speculum examination, then bimanual examination
Number of subjects: 200
Study 29474289 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Q‐tip touch test, bimanual examination, then speculum examination
Number of subjects: 200
Study 29474289 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly defined in the abstract)
Number of subjects: 200
Study 27544458 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Through Choices (PTC) intervention
Number of subjects: 1037
Study 27544458 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1037
Study 25371275 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID patch (ketoprofen)
Number of subjects: 99
Study 25371275 — intervention group
Group type: COMPARATOR
Intervention: NSAID patch + TENS
Number of subjects: 99
Study 25371275 — intervention group
Group type: COMPARATOR
Intervention: NSAID patch + heating pad
Number of subjects: 99
Study 25371275 — intervention group
Group type: COMPARATOR
Intervention: NSAID patch + topical capsaicin
Number of subjects: 99
Study 22260861 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture beverage (CHO/AA) consisting of 0.088 g cystine 2HCl, 0.043 g methionine, 0.086 g valine, 12.094 g isoleucine, 0.084 g leucine, and 100 g dextrose
Number of subjects: 22
Study 22260861 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (CHO) consisting of 100 g dextrose only
Number of subjects: 22
Study 22260861 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture beverage (CHO/AA)
Number of subjects: 22
Study 22260861 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (CHO)
Number of subjects: 22
Study 20230319 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hyperbaric bupivacaine
Number of subjects: 103
Study 20230319 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg plain bupivacaine
Number of subjects: 103
Study 20230319 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg hyperbaric ropivacaine with fentanyl 20 μg
Number of subjects: 103
Study 20230319 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg plain ropivacaine with fentanyl 20 μg
Number of subjects: 103
Study 17053207 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (50/500 micro g) twice daily
Number of subjects: 994
Study 17053207 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 micro g) twice daily
Number of subjects: 994
Study 15597187 — intervention group
Group type: EXPERIMENTAL
Intervention: Route descriptions
Number of subjects: 0
Study 15597187 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey descriptions
Number of subjects: 0
Study 15597187 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition/priming task and bird-flight distance comparison task
Number of subjects: 0
Study 15597187 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic distance effects
Number of subjects: 0
Study 12237186 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture at distant points
Number of subjects: 36
Study 12237186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) of local myofascial trigger points
Number of subjects: 36
Study 12237186 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture (Sham)
Number of subjects: 36
Study 8530854 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBG scintigraphy
Number of subjects: 25
Study 8530854 — intervention group
Group type: COMPARATOR
Intervention: TI scintigraphy
Number of subjects: 25
Study 1496838 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-bathing series with light-motion therapy
Number of subjects: 12
Study 1496838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cure)
Number of subjects: 12
Study 6648053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen (2-mg tablet of salbutamol + 10 puffs of salbutamol inhalation)
Number of subjects: 10
Study 6648053 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation (100 micrograms per puff)
Number of subjects: 10
Study 6648053 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol tablet
Number of subjects: 10
Study 6648053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablet and inhalation)
Number of subjects: 10
Study 30362989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Index of Mortality 3
Number of subjects: 1428
Study 30362989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Risk of Mortality III
Number of subjects: 1428
Study 29758508 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio™ Tape (KT)
Number of subjects: 12
Study 29758508 — intervention group
Group type: EXPERIMENTAL
Intervention: RockTape™ (RT)
Number of subjects: 12
Study 29758508 — intervention group
Group type: COMPARATOR
Intervention: No tape (NT)
Number of subjects: 12
Study 25222428 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP and standard therapy
Number of subjects: 20
Study 24952044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine
Number of subjects: 0
Study 24952044 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular lidocaine
Number of subjects: 0
Study 24952044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine and lidocaine
Number of subjects: 0
Study 21909946 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback (visualization of charts showing the progression of disease activity parameters) added to DMARDs therapy
Number of subjects: 111
Study 21909946 — intervention group
Group type: COMPARATOR
Intervention: Standard management protocols (Control group)
Number of subjects: 111
Study 21909946 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback (visualization of charts showing the progression of disease activity parameters)
Number of subjects: 111
Study 21228500 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen-loading regimen (3-day high-fat diet followed by 3-day high-carbohydrate diet)
Number of subjects: 0
Study 21228500 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (6-day duration)
Number of subjects: 0
Study 18453320 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat cereal (5.7 g/day beta-glucan)
Number of subjects: 27
Study 18453320 — intervention group
Group type: COMPARATOR
Intervention: Wheat cereal (control)
Number of subjects: 27
Study 16635963 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtica dioica
Number of subjects: 620
Study 16635963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 12010697 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a personal‐office‐visit diary
Number of subjects: 1038
Study 12010697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diary)
Number of subjects: 1038
Study 10529510 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori positive gastritis
Number of subjects: 45
Study 10529510 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative gastritis
Number of subjects: 45
Study 10529510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 10529510 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative chronic gastritis
Number of subjects: 45
Study 8530122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-expressed empathy measures (Behavioral Test of Interpersonal Skills and Staff-Patient Interaction Response Scale)
Number of subjects: 140
Study 8530122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-expressed empathy measures
Number of subjects: 140
Study 2338469 — intervention group
Group type: EXPERIMENTAL
Intervention: Polocaine (mepivacaine hydrochloride)
Number of subjects: 40
Study 7297020 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg carteolol
Number of subjects: 0
Study 7297020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg carteolol
Number of subjects: 0
Study 7297020 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg carteolol
Number of subjects: 0
Study 7297020 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg carteolol
Number of subjects: 0
Study 7297020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31270291 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec U100 (IDeg)
Number of subjects: 74
Study 31270291 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 (IGla)
Number of subjects: 74
Study 27634976 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg daily aspirin
Number of subjects: 559
Study 27634976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study 28039289 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical mask (n=123)
Number of subjects: 245
Study 28039289 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask group (household members of index cases who used a mask)
Number of subjects: 245
Study 28039289 — intervention group
Group type: COMPARATOR
Intervention: No-mask group (household members of index cases who did not use a mask)
Number of subjects: 245
Study 24954805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (paclitaxel then UFT)
Number of subjects: 1495
Study 24954805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (paclitaxel then S-1)
Number of subjects: 1495
Study 24954805 — intervention group
Group type: COMPARATOR
Intervention: UFT monotherapy
Number of subjects: 1495
Study 24954805 — intervention group
Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 1495
Study 23098579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated tomotherapy (TT) - 15 × 2.8 Gy over 3 weeks, with a simultaneous integrated boost of 15 × 0.6 Gy over 3 weeks for BCS patients
Number of subjects: 121
Study 23098579 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CR) - 25 × 2 Gy over 5 weeks, with a sequential boost of 8 × 2 Gy over 2 weeks for BCS patients
Number of subjects: 121
Study 19730900 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg/day
Number of subjects: 86
Study 19730900 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (vancomycin 1 g every 12 h or antistaphylococcal penicillin 2 g every 4 h, both with gentamicin 1 mg/kg every 8 h for 4 days)
Number of subjects: 86
Study 19730900 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 86
Study 19730900 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 86
Study 17514173 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive lateral approach THA (study group)
Number of subjects: 120
Study 17514173 — intervention group
Group type: COMPARATOR
Intervention: Standard lateral direct approach THA (control group)
Number of subjects: 120
Study 17514173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 120
Study 15368619 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy (group I)
Number of subjects: 56
Study 15368619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament reconstruction/tendon interposition (group II)
Number of subjects: 56
Study 11173126 — intervention group
Group type: EXPERIMENTAL
Intervention: Very large trials
Number of subjects: 0
Study 11173126 — intervention group
Group type: EXPERIMENTAL
Intervention: Small trials based on biologic hypotheses
Number of subjects: 0
Study 11173126 — intervention group
Group type: COMPARATOR
Intervention: Individualized strategies among patients with histologically similar tumors
Number of subjects: 0
Study 9509352 — intervention group
Group type: EXPERIMENTAL
Intervention: PISA method
Number of subjects: 33
Study 9509352 — intervention group
Group type: COMPARATOR
Intervention: Jet area method
Number of subjects: 33
Study 7810090 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Mack retard + Moduretic (diuretic)
Number of subjects: 24
Study 7810090 — intervention group
Group type: COMPARATOR
Intervention: Iso‐Mack retard (nitrate)
Number of subjects: 24
Study 7810090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3133703 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study 3133703 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic drink
Number of subjects: 12
Study 3133703 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 12
Study 30001923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg once-daily
Number of subjects: 106
Study 30001923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 28634650 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-360 60 mg
Number of subjects: 0
Study 28634650 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-360 120 mg
Number of subjects: 0
Study 28634650 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-360 240 mg
Number of subjects: 0
Study 28634650 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (Gem group)
Number of subjects: 0
Study 25413958 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ASV (PaceWave)
Number of subjects: 0
Study 25413958 — intervention group
Group type: COMPARATOR
Intervention: Conventional ASV (AutoSetCS)
Number of subjects: 0
Study 24282867 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpik Water Flosser plus a manual toothbrush (WF)
Number of subjects: 70
Study 24282867 — intervention group
Group type: COMPARATOR
Intervention: waxed string floss plus a manual toothbrush (SF)
Number of subjects: 70
Study 20438578 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN monotherapy at a dosage of 0.8 μg/kg per week (n = 12)
Number of subjects: 24
Study 20438578 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (0.8 μg/kg per week) plus RIB (800‐1200 mg/d) (n = 12)
Number of subjects: 24
Study 20438578 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN monotherapy
Number of subjects: 24
Study 20438578 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN plus RIB
Number of subjects: 24
Study 20438578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 24
Study 19502420 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 14
Study 19502420 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 14
Study 19502420 — intervention group
Group type: COMPARATOR
Intervention: Control (matched control subjects)
Number of subjects: 14
Study 16814949 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy +/− androgen deprivation
Number of subjects: 119
Study 12869355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐estradiol orally + 100 mg progesterone daily
Number of subjects: 196
Study 12869355 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg 17beta‐estradiol transdermally per day + 100 mg progesterone daily
Number of subjects: 196
Study 12869355 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 100 mg progesterone daily
Number of subjects: 196
Study 10832774 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0